These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37950531)

  • 1. Psychiatric disorders associated with PCSK9 inhibitors: A real-world, pharmacovigilance study.
    Deng Z; Liu J; Gong H; Cai X; Xiao H; Gao W
    CNS Neurosci Ther; 2024 Apr; 30(4):e14522. PubMed ID: 37950531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study.
    Goldman A; Raschi E; Cukierman-Yaffe T; Dankner R; Shouval R; Shechter M; Ben-Zvi I; Gerstein HC; Maor E
    Eur J Prev Cardiol; 2022 Jul; 29(9):1334-1342. PubMed ID: 34897409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
    Chen W; Cai P; Zou W; Fu Z
    Front Endocrinol (Lausanne); 2024; 15():1330936. PubMed ID: 38390214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system.
    Ji C; Bai J; Zhou J; Zou Y; Yu M
    Br J Clin Pharmacol; 2022 Dec; 88(12):5317-5325. PubMed ID: 35818959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular disorders associated with PCSK9 inhibitors: A pharmacovigilance disproportionality analysis.
    Zhao X; Wu J; Zhu S
    Br J Clin Pharmacol; 2023 Feb; 89(2):458-469. PubMed ID: 35973681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS.
    Feng Z; Li X; Tong WK; He Q; Zhu X; Xiang X; Tang Z
    Front Pharmacol; 2022; 13():894685. PubMed ID: 36506552
    [No Abstract]   [Full Text] [Related]  

  • 7. Spectrum of psychiatric adverse reactions to cyclin-dependent kinases 4/6 inhibitors: A pharmacovigilance analysis of the FDA adverse event reporting system.
    Xiao Z; Cao J; Wu S; Zhou T; Li C; Duan J; Yang Z; Xu F
    CNS Neurosci Ther; 2024 Jul; 30(7):e14862. PubMed ID: 39009505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCSK9 Inhibitors and Infection-Related Adverse Events: A Pharmacovigilance Study Using the World Health Organization VigiBase.
    Park D; Bea S; Bae JH; Lee H; Choe YJ; Shin JY; Kim H
    Drugs Real World Outcomes; 2024 Sep; 11(3):465-475. PubMed ID: 38954190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system.
    Shu Y; Chen J; Ding Y; Zhang Q
    Front Immunol; 2023; 14():1169735. PubMed ID: 37256136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
    Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
    BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurocognitive Disorders Associated with PCSK9 Inhibitors: a Pharmacovigilance Disproportionality Analysis.
    Gouverneur A; Sanchez-Pena P; Veyrac G; Salem JE; Bégaud B; Bezin J
    Cardiovasc Drugs Ther; 2023 Apr; 37(2):271-276. PubMed ID: 34436707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Ding L; Chen C; Yang Y; Fang J; Cao L; Liu Y
    Cardiovasc Ther; 2022; 2022():9866486. PubMed ID: 35140810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database.
    Sun R; Ning Z; Qin H; Zhang W; Teng Y; Jin C; Liu J; Wang A
    Sci Rep; 2024 Apr; 14(1):9552. PubMed ID: 38664423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.
    Sato K; Mano T; Iwata A; Toda T
    Biosci Trends; 2020 May; 14(2):139-143. PubMed ID: 32321905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of Monoclonal Antibodies Inhibiting PCSK9 in Pregnancy: Disproportionality Analysis in VigiBase®.
    Noseda R; Bedussi F; Panchaud A; Ceschi A
    Clin Pharmacol Ther; 2024 Aug; 116(2):346-350. PubMed ID: 38637956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse Events Associated With PCSK9 Inhibitors: A Real-World Experience.
    Gürgöze MT; Muller-Hansma AHG; Schreuder MM; Galema-Boers AMH; Boersma E; Roeters van Lennep JE
    Clin Pharmacol Ther; 2019 Feb; 105(2):496-504. PubMed ID: 30053327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pregnancy-related adverse events associated with statins: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS).
    Wu T; Shi Y; Zhu B; Li D; Li Z; Zhao Z; Zhang Y
    Expert Opin Drug Saf; 2024 Mar; 23(3):313-321. PubMed ID: 37612600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
    Yin Y; Shu Y; Zhu J; Li F; Li J
    Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system.
    Shu Y; Ding Y; Liu L; Zhang Q
    CNS Neurosci Ther; 2023 Sep; 29(9):2705-2716. PubMed ID: 37032639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.